Insmed reported $-101451000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
DBV Technologies DBVT:US -16771000 2.37M
Acelrx Pharmaceuticals ACRX:US $ -8995000 820K
Alimera Sciences ALIM:US $ -4147000 1.4M
Biomarin Pharmaceutical BMRN:US $ 29.33M 95.21M
Cytokinetics CYTK:US $ -77857000 58.95M
Dynavax Technologies DVAX:US $ 31.47M 49.67M
Gilead Sciences GILD:US $ 2897M 1957M
Heron Therapeutics HRTX:US $ -62923000 9.39M
Insmed INSM:US $ -101451000 1.41M
Mirati Therapeutics MRTX:US $ -184218000 12.86M
Novartis NVS:US 3.15B 266M
Ophthotech OPHT:US $ -34670000 1.57M
Regeneron Pharmaceuticals REGN:US $ 1286.6M 1353.1M
Sarepta Therapeutics SRPT:US $ -86881000 18.93M
Seattle Genetics SGEN:US $ -133050000 39.02M
Ultragenyx Pharmaceutical RARE:US $ -136632000 34.07M
Vertex Pharmaceuticals VRTX:US $ 1033.4M 157.68M